178 related articles for article (PubMed ID: 19440214)
1. Thalidomide exerts distinct molecular antileukemic effects and combined thalidomide/fludarabine therapy is clinically effective in high-risk chronic lymphocytic leukemia.
Giannopoulos K; Dmoszynska A; Kowal M; Wasik-Szczepanek E; Bojarska-Junak A; Rolinski J; Döhner H; Stilgenbauer S; Bullinger L
Leukemia; 2009 Oct; 23(10):1771-8. PubMed ID: 19440214
[TBL] [Abstract][Full Text] [Related]
2. Oral fludarabine and cyclophosphamide as front-line chemotherapy in patients with chronic lymphocytic leukemia. The impact of biological parameters in the response duration.
Laurenti L; Tarnani M; De Padua L; Efremov DG; Zini G; Garzia M; Piccirillo N; Chiusolo P; Sorà F; Innocenti I; Sica S; Leone G
Ann Hematol; 2008 Nov; 87(11):891-8. PubMed ID: 18587576
[TBL] [Abstract][Full Text] [Related]
3. Low-dose thalidomide in combination with oral fludarabine and cyclophosphamide is ineffective in heavily pre-treated patients with chronic lymphocytic leukemia.
Laurenti L; Piccioni P; Tarnani M; De Padua L; Garzia M; Efremov DG; Piccirillo N; Chiusolo P; Sica S; Leone G
Leuk Res; 2007 Feb; 31(2):253-6. PubMed ID: 16815546
[TBL] [Abstract][Full Text] [Related]
4. Low-dose thalidomide in combination with oral fludarabine and cyclophosphamide is ineffective in heavily pretreated patients with chronic lymphocytic leukemia.
Giannopoulos K; Dmoszyńska A; Roliński J
Leuk Res; 2007 Mar; 31(3):411-2. PubMed ID: 16978694
[No Abstract] [Full Text] [Related]
5. Fludarabine, cyclophosphamide, and mitoxantrone as initial therapy of chronic lymphocytic leukemia: high response rate and disease eradication.
Bosch F; Ferrer A; Villamor N; González M; Briones J; González-Barca E; Abella E; Gardella S; Escoda L; Pérez-Ceballos E; Asensi A; Sayas MJ; Font L; Altés A; Muntañola A; Bertazzoni P; Rozman M; Aymerich M; Giné E; Montserrat E
Clin Cancer Res; 2008 Jan; 14(1):155-61. PubMed ID: 18172266
[TBL] [Abstract][Full Text] [Related]
6. Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy.
Byrd JC; Gribben JG; Peterson BL; Grever MR; Lozanski G; Lucas DM; Lampson B; Larson RA; Caligiuri MA; Heerema NA
J Clin Oncol; 2006 Jan; 24(3):437-43. PubMed ID: 16344317
[TBL] [Abstract][Full Text] [Related]
7. Comparison of cladribine plus cyclophosphamide with fludarabine plus cyclophosphamide as first-line therapy for chronic lymphocytic leukemia: a phase III randomized study by the Polish Adult Leukemia Group (PALG-CLL3 Study).
Robak T; Jamroziak K; Gora-Tybor J; Stella-Holowiecka B; Konopka L; Ceglarek B; Warzocha K; Seferynska I; Piszcz J; Calbecka M; Kostyra A; Dwilewicz-Trojaczek J; Dmoszyñska A; Zawilska K; Hellmann A; Zdunczyk A; Potoczek S; Piotrowska M; Lewandowski K; Blonski JZ
J Clin Oncol; 2010 Apr; 28(11):1863-9. PubMed ID: 20212251
[TBL] [Abstract][Full Text] [Related]
8. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia.
Rai KR; Peterson BL; Appelbaum FR; Kolitz J; Elias L; Shepherd L; Hines J; Threatte GA; Larson RA; Cheson BD; Schiffer CA
N Engl J Med; 2000 Dec; 343(24):1750-7. PubMed ID: 11114313
[TBL] [Abstract][Full Text] [Related]
9. Comparison between oral and intravenous fludarabine plus cyclophosphamide regime as front-line therapy in patients affected by chronic lymphocytic leukaemia: influence of biological parameters on the clinical outcome.
Laurenti L; De Padua L; Tarnani M; Piccirillo N; Falcucci P; D'Arena G; Innocenti I; Marietti S; Efremov DG; Chiusolo P; Zini G; Sora' F; Sica S; Leone G
Ann Hematol; 2011 Jan; 90(1):59-65. PubMed ID: 20625902
[TBL] [Abstract][Full Text] [Related]
10. Serum tumor necrosis factor-α and interleukin-10 levels as markers to predict outcome of patients with chronic lymphocytic leukemia in different risk groups defined by the IGHV mutation status.
Lech-Maranda E; Grzybowska-Izydorczyk O; Wyka K; Mlynarski W; Borowiec M; Antosik K; Cebula-Obrzut B; Makuch-Lasica H; Nowak G; Klimkiewicz-Wojciechowska G; Wawrzyniak E; Bilinski P; Robak T; Warzocha K
Arch Immunol Ther Exp (Warsz); 2012 Dec; 60(6):477-86. PubMed ID: 22945689
[TBL] [Abstract][Full Text] [Related]
11. Fludarabine + prednisone +/- alpha-interferon followed or not by alpha-interferon maintenance therapy for previously untreated patients with chronic lymphocytic leukemia: long term results of a randomized study.
Mauro FR; Zinzani P; Zaja F; Gentile M; Vegna ML; Stefoni V; Marin L; Fanin R; Baccarani M; Tura S; Mandelli F
Haematologica; 2003 Dec; 88(12):1348-57. PubMed ID: 14687987
[TBL] [Abstract][Full Text] [Related]
12. p53 Aberrations do not predict individual response to fludarabine in patients with B-cell chronic lymphocytic leukaemia in advanced stages Rai III/IV.
Valgañón M; Giraldo P; Agirre X; Larráyoz MJ; Rubio-Martinez A; Rubio-Felix D; Calasanz MJ; Odero MD
Br J Haematol; 2005 Apr; 129(1):53-9. PubMed ID: 15801955
[TBL] [Abstract][Full Text] [Related]
13. CD40 triggering enhances fludarabine-induced apoptosis of chronic lymphocytic leukemia B-cells through autocrine release of tumor necrosis factor-alpha and interferon-gama and tumor necrosis factor receptor-I-II upregulation.
de Totero D; Tazzari PL; Capaia M; Montera MP; Clavio M; Balleari E; Foa R; Gobbi M
Haematologica; 2003 Feb; 88(2):148-58. PubMed ID: 12604404
[TBL] [Abstract][Full Text] [Related]
14. Chronic lymphocytic leukemia: current and emerging treatment approaches.
Kay NE; Rai KR; O'Brien S
Clin Adv Hematol Oncol; 2006 Nov; 4(11 Suppl 22):1-10; quiz 11-2. PubMed ID: 17143256
[TBL] [Abstract][Full Text] [Related]
15. Antileukemic activity of valproic acid in chronic lymphocytic leukemia B cells defined by microarray analysis.
Stamatopoulos B; Meuleman N; De Bruyn C; Mineur P; Martiat P; Bron D; Lagneaux L
Leukemia; 2009 Dec; 23(12):2281-9. PubMed ID: 19710697
[TBL] [Abstract][Full Text] [Related]
16. Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997.
Flinn IW; Neuberg DS; Grever MR; Dewald GW; Bennett JM; Paietta EM; Hussein MA; Appelbaum FR; Larson RA; Moore DF; Tallman MS
J Clin Oncol; 2007 Mar; 25(7):793-8. PubMed ID: 17283364
[TBL] [Abstract][Full Text] [Related]
17. Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia.
O'Brien S; Moore JO; Boyd TE; Larratt LM; Skotnicki A; Koziner B; Chanan-Khan AA; Seymour JF; Bociek RG; Pavletic S; Rai KR
J Clin Oncol; 2007 Mar; 25(9):1114-20. PubMed ID: 17296974
[TBL] [Abstract][Full Text] [Related]
18. Concomitant administration of chlorambucil limits dose intensity of fludarabine in previously treated patients with chronic lymphocytic leukemia.
Weiss M; Spiess T; Berman E; Kempin S
Leukemia; 1994 Aug; 8(8):1290-3. PubMed ID: 8057664
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of lymphocyte morphology in patients with advanced chronic lymphocytic leukemia treated with first line therapy of fludarabine + prednisone.
Mauro FR; Gentile M; Mancini F; Giannarelli D; Guarini A; De Propriis MS; Cerretti R; Foa R
Haematologica; 2002 Jun; 87(6):602-8. PubMed ID: 12031916
[TBL] [Abstract][Full Text] [Related]
20. [Prognostic significance of immunoglobulin variable region gene mutations in B-CLL patients treated with combination therapy fludarabine plus cyclophosphamide].
Nikitin EA; Stadnik EA; Lorie IuIu; Biderman BV; Tsyba NN; Salogub GN; Kolosheĭnova TI; Kolosova LIu; Risinskaia NA; Zaritskiĭ IuA; Kovaleva LG; Sudarikov AB
Ter Arkh; 2007; 79(7):66-70. PubMed ID: 17802794
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
